News Releases

Year

April 18, 2022

Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022

Automated benchtop BioXp™ system offers significant quality, time, and cost advantages for DNA and mRNA synthesis compared to alternative options SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced

April 6, 2022

Codex DNA to Showcase Innovative SOLA Enzymatic DNA Synthesis Technology and Automated Benchtop BioXp System at SynBioBeta’s Built with Biology Global Conference

SOLA approach has the potential to be more accurate, scalable, and cost-effective compared to traditional chemical synthesis and alternative enzymatic techniques for constructing DNA SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop

March 22, 2022

Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guidance for 2022.

March 3, 2022

Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced details for its first Investor R&D Webinar. Management will describe the future promise of the company’s R&D pipeline, with a specific focus on

March 2, 2022

Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the market closes.

February 24, 2022

Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present virtually at the 42 nd Annual Cowen Healthcare Conference on

February 9, 2022

Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be participating in the SVB Leerink 11 th Annual Global Healthcare Conference.

January 18, 2022

Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

Proprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virus Initial performance results show potentially significant quality, time, and cost advantages compared to traditional

January 10, 2022

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies

Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technology Pfizer’s successful development and commercialization of licensed products could result in milestone payments in excess of $100 million SAN

First page
Previous page
Page 1
Current page 2

Displaying 11 - 19 of 19

Investor Relations

News & Events menu